This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Celgene’s performance against key rivals in the prescription pharmaceutical sector
Understand how Revlimid will drive the company’s performance out to 2013
See how the acquisition of Pharmion will affect Celgene’s strategy
Analysis service - track your competitors, and identify new partners. Qualitative and quantitative company and portfolio analysis for the leading pharmaceutical and biotechnology companies in the US, Europe and Japan, and detailed analysis of key market sectors with detailed coverage of key players.Including analysis of their company strategy, product portfolio, and development pipeline, with forecasting.
